Functional genomics: Clinical effect and the evolving role of the surgeon

Archives of Surgery

Volumn 134, Issue 11, 1999, Pages 1209-1215

  Hernandez, Ambrosio ^a   Evers, B Mark ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLONING; GENE TARGETING; GENE THERAPY; GENETIC ANALYSIS; HUMAN; MEDICAL GENETICS; ONCOGENE; PRIORITY JOURNAL; REVIEW; SURGEON; TRANSPLANTATION; WOUND HEALING;

EID: 0032727974     PISSN: 00040010     EISSN: None     Source Type: Journal    
DOI: 10.1001/archsurg.134.11.1209     Document Type: Review

References (58)

1. Collins FS. Shattuck Lecture: medical and societal consequences of the Human Genome Project. N Engl J Med. 1999;341:28-37.
2. Collins FS, Patrinos A, Jordan E, Chakravarti A, Gesteland R, Walters L. New goals for the US Human Genome Project: 1998-2003. Science. 1998;282:682-689.
3. Pennisi E. Acloser look at SNPs suggests difficulties. Science. 1998;281:1787-1789.
4. Chakravarti A. It's raining SNPs, hallelujah? Nat Genet. 1998;19:216-217.
5. Wang DG, Fan JB, Siao CJ, et al. Large-scale identification, mapping, and genotyping of single-nucleotide polymorphisms in the human genome. Science. 1998; 280:1077-1082.
6. Cargill M, Altshuler D, Ireland J, et al. Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nat Genet. 1999;22:231-238.
7. Moulton G. Surgeons have critical role in genetic testing decisions, medical, legal experts say. J Natl Cancer Inst. 1998;90:804-805.
8. Dahiya R, Deng G. Molecular prognostic markers in breast cancer. Breast Cancer Res Treat. 1998;52:185-200.
9. Vogelstein BJ. Genetic testing for cancer: the surgeon's critical role: familial colon cancer. Am Coll Surg. 1999;188:74-79.
10. Mollnes TE, Fiane AE. Xenotransplantation: how to overcome the complement obstacle? Mol Immunol. 1999;36:269-276.
11. Bloom ET, Moulton AD. Xenotransplantation: the potential and the challenges. Crit Care Nurse. 1999;19:76-83.
12. Rosenberg G, Snyder AJ, Weiss WJ, et al. Dynamic in vitro and in vivo performance of a permanent total artificial heart. Artif Organs. 1998;22:87-94.
13. Tackaberry ES, Ganz PR. Xenotransplantation: assessing the unknowns. CMAJ. 1998;159:41-43.
14. Chapman LE, Folks TM, Salomon DR, Patterson AP, Eggerman TE, Noguchi PD. Xenotransplantation and xenogeneic infections. N Engl J Med. 1995;333:1498-1501.
15. Wadman M. US stem-cell pioneers buy "Dolly" cloning company. Nature. 1999; 399:92.
16. Solter D. Dolty is a clone - and no longer alone. Nature. 1998;394:315-316.
17. Solter D. Cloning claims challenged [letter]. Nature. 1999;399:13.
18. Anderson GB, Seidel GE. Cloning for profit. Science. 1999;280:1400-1401.
19. Bagnis C, Mannoni P. Stern cell-based gene therapy. Oncologist. 1997;2:196-202.
20. Drozdzik M, Qian C, Lasarte JJ, Bilbao R, Prieto J. Antitumor effect of allogenic fibroblasts engineered to express Fas ligand (FasL). Gene Ther. 1998;5:1622-1630.
21. Cibelli JB, Stice SL, Golueke PJ, et al. Cloned transgenic calves produced from nonquiescent fetal fibroblasts. Science. 1998;280:1256-1258.
22. Coutts MC. Human gene therapy. Washington, DC: National Reference Center for Bioethics Literature; 1998. Scope note 24. Available at: http://www.georgetown.edu/ research/nrcbl/scopenotes/sn24.htm. Accessed August 26, 1999.
23. Syngal S, Fox EA, Li C, et al. Interpretation of genetic test results for hereditary nonpolyposis colorectal cancer: implications for clinical predisposition testing. JAMA. 1999;282:247-253.
24. Tomlinson GE. Familial cancer syndromes and genetic counseling. Cancer Treat Res. 1997;92:63-97.
25. Balis FM. The challenge of developing new therapies for childhood cancers. Oncologist. 1997;2:1-11.
26. Vasen HF, van der Luijt RB, Slors JF, et al. Molecular genetic tests as a guide to surgical management of familial adenomatous polyposis. Lancet 1996;348:433-435.
27. Hurwitz MY, Marcus KT, Chevez-Barrios P, Louie K, Aguilar-Cordova E, Hurwitz RL. Suicide gene therapy for treatment of retinoblastoma in a murine model. Hum Gene Ther. 1999;10:441-448.
28. Perez-Cruet MJ, Trask TW, Chen SH, et al. Adenovirus-mediated gene therapy of experimental gliomas. J Neurosci Res. 1994;39:506-511.
29. Guillem JG, Smith AJ, Calle JP, Ruo L. Gastrointestinal polyposis syndromes. Curr Probl Surg. 1999;36:217-323.
30. Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995;378:789-792.
31. Dralle H, Gimm O, Simon O. et al. Prophylactic thyroidectomy in 75 children and adolescents with hereditary medullary thyroid carcinoma: German and Austrian experience. World J Surg. 1998;22:744-750.
32. Skinner MA, DeBenederti MK, Moley JF, Norton JA, Wells SA Jr. Medullary thyroid carcinoma in children with multiple endocrine neoplasia types 2A and 2B. J Pediatr Surg. 1996;31:177-181.
33. Spear SL, Pennanen M, Barter J, Burke JB. Prophylactic mastectomy, oophorectomy, hysterectomy, and immediate transverse rectus abdominis muscle flap breast reconstruction in a BRCA-2-positive patient. Plast Reconstr Surg. 1999; 103:548-553.
34. Wilcox-Honnold PM. Breast cancer and gene testing: risk, rationale, and responsibilities of primary care providers. Lippincotts Prim Care Pract. 1998;2:271 -283.
35. Ormiston W. Hereditary breast cancer. EurJ Cancer Care (Engl). 1996;5:13-20.
36. Berry DA, Parmigiani G, Sanchez J, et al. Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. J Natl Cancer Inst 1997;89:227-238.
37. Phelan CM, Rebbeck TR, Weber BL, et al. Ovarian cancer risk in BRCA1 carriers is modified by the HRAS1 variable number of tandem repeat (VNTR) locus. Nat Genet. 1996;12:309-310.
38. Grann RV, Panageas KS, Whang W, et al. Decisions analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients. J Clin Oncol. 1998;16:979-985.
39. Eisen A, Weber BL. Prophylactic mastectomy: the price of fear. N Engl J Med. 1999;340:137-138.
40. Davidson JM, Whitsitt JS, Pennington B, Ballas CB, Eming S, Benn SI. Gene therapy of wounds with growth factors. Curr Top Pathol. 1999;93:111-121.
41. Eming SA, Morgan JR, Berger A. Gene therapy for tissue repair: approaches and prospects. Br J Plast Surg. 1997;50:491-500.
42. Quintero RF. Diagnostic fetoscopy. Tampa: Florida Institute for Fetal Diagnosis and Therapy; 1999. Available at: http://www.fetalmd.com/fetoscopy.htm. Accessed August 26, 1999.
43. van Heteren CF, Nijhuis JG, Semmekrot BA, Mulders LG, van den Berg PP. Risk for surviving twin after fetal death of co-twin in twin-twin transfusion syndrome. Obstet Gynecol. 1998;92:215-219.
44. Jaroff L. Fixing the genes. Time. May 17, 1999;153:68-70, 73.
45. McCarrick PM. Genetic testing and genetic screening. Washington, DC: National Reference Centerfor Bioethics Literature; 1997. Scope note 22. Available at: http://www.georgetown.edu/research/nrcbl/scopenotes/sn22.htm. Accessed August 30, 1999.
46. Chen PW, Wang M, Bronte V, Zhai Y, Rosenberg SA, Restifo NP. Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen. J Immunol. 1996;156:224-231.
47. Ettinghausen SE, Rosenberg SA. Immunotherapy and gene therapy of cancer. Adv Surg. 1995;28:223-254.
48. Rosenberg SA, Blaese PM, Brenner MK, et al. Human gene marker/therapy clinical protocols. Hum Gene Ther. 1997;8:2301-2338.
49. Burgess MM, Laberge CM, Knoppers BM. Bioethics for clinicians, 14: ethics and genetics in medicine. CMAJ. 1998;158:1309-1313.
50. Vineis P. Ethical issues in genetic screening for cancer. Am Oncol. 1997;8:945-949.
51. Grady C. Ethics and genetic testing. Adv Intern Med. 1999;44:389-411.
52. Holtzman NA, Shapiro D. The new genetics: genetic testing and public policy. BMJ. 1998;316:852-856.
53. Marteau TM, Croyle RT. The new genetics: psychological responses to genetic testing. BMJ. 1998;316:693-696.
54. Markham IS. Ethical and legal issues. Br Med Bull. 1998;54:1011-1021.
55. Holtzman N, Watson M, eds. Promoting Safe and Effective Genetic Testing in the United States: Final Report of the Task Force on Genetic Testing. Baltimore, Md: Johns Hopkins University Press; 1998.
56. Rothenberg K, Fuller B, Rolhstein M, et al. Genetic information and the workplace: legislative approaches and policy changes. Science. 1997;275:1755-1757.
57. Equal Employment Opportunity Commission. Compliance Manual. Washington, DC: Equal Employment Opportunity Commission; March 15, 1995. Section 902.
58. Hudson KL, Rothenberg KH, Andrews LB, Kahn MJ, Collins FS. Genetic discrimination and health insurance: an urgent need for reform. Science. 1995;270:391-393.